查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925859

免疫腫瘤服務市場（依治療方法、癌症適應症、最終用戶和通路分類）－2026年至2032年全球預測

Immuno-Oncology Service Market by Therapy Type, Cancer Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，免疫腫瘤服務市場價值將達到 467.7 億美元，到 2026 年將成長至 502.3 億美元，到 2032 年將達到 786.2 億美元，複合年成長率為 7.70%。

關鍵市場統計數據
基準年 2025 467.7億美元
預計年份：2026年 502.3億美元
預測年份 2032 786.2億美元
複合年成長率 (%) 7.70%

將科學進展、監管環境和商業性需求整合起來，形成對現代免疫腫瘤學格局的連貫策略概述。

免疫腫瘤學領域正處於一個轉折點，科學進步、監管變革和商業性壓力交織在一起，重新定義了癌症療法的發現、開發和應用方式。免疫調節劑、細胞療法和精準疫苗的最新進展正在拓展血液腫瘤和固態腫瘤的治療可能性，而對腫瘤生物學和宿主免疫的日益深入的理解也在重塑臨床策略。同時，醫療系統、付款者和患者都要求獲得更清晰的療效持久性、可控毒性和成本效益的證據，這促使申辦方採用更全面的證據路徑。

科學突破、製造創新和監管調整共同揭示了重塑免疫腫瘤學研發和治療的新趨勢

免疫腫瘤學正經歷一場變革，這場變革的驅動力來自於技術創新、策略合作以及貫穿整個研發生命週期的系統性調整。細胞工程和新一代查核點調控技術的進步，正在拓展治療的可能性，使其超越傳統的單一療法，從而實現個人化的多模態治療方法，旨在克服抗藥性機制並深化臨床療效。同時，日益成熟的伴隨診斷和新抗原識別平台，能夠實現更精準的患者分層，簡化臨床試驗流程，並提高獲得具有臨床意義結果的可能性。

評估2025年關稅調整對專業供應鏈、製造地地點和臨床開發計畫的營運和策略影響

2025年美國關稅政策的變化為全球生物製藥供應鏈引入了新的變數。這些變化對免疫腫瘤領域的相關人員影響尤其顯著，因為該領域高度依賴專業原料、低溫運輸物流和跨境生產夥伴關係。試劑、一次性耗材和設備的關稅調整直接推高了採購成本，迫使申辦者和契約製造製造商重新評估籌資策略和庫存管理政策。這些變化凸顯了多元化供應商網路和近岸外包方案的重要性，這些方案有助於降低跨境關稅和物流中斷的風險，同時確保產品品質和合規性。

揭示治療方法、臨床適應症、臨床環境和通路之間相互依存的細分動態，以幫助制定有針對性的開發和商業化策略。

細分市場分析揭示了治療方法、癌症適應症、終端用戶和分銷管道如何影響免疫腫瘤價值鏈中的策略重點和營運執行。在治療方法模式方面，以癌症疫苗為重點的研究包括基於細胞、基因和胜肽的療法，每種療法都有不同的研發週期和生產要求。基於細胞的疫苗需要個人化的生產流程，而基因疫苗則依賴核酸遞送平台和低溫運輸最佳化。同時，基於胜肽的療法具有標準化生產的優勢，可以加速臨床試驗。嵌合體抗原受體T細胞療法包括標靶BCMA和標靶CD19的構建體，它們針對不同的骨髓惡性腫瘤，因此需要個人化的試驗設計、安全性監測和長期追蹤通訊協定。查核點抑制劑項目因作用機製而異，CTLA-4、PD-1和PD-L1抑制劑各自具有不同的安全性特徵和合併用藥機會。此外，單株抗體策略（嵌合體、全人源抗體、人源化抗體）在免疫抗原性風險、生產複雜性和商業可行性方面各不相同。

繪製區域基礎設施、監管差異和報銷框架如何影響臨床應用和商業化選擇。

區域趨勢反映了醫療基礎設施、報銷環境和臨床試驗生態系統的差異，這些差異在塑造免疫腫瘤產品的研究重點、監管策略和商業化路徑方面發揮著至關重要的作用。在美洲，學術研究機構的集中、完善的報銷機制以及經驗豐富的合約研發生產機構（CDMO）共同支持複雜的臨床研究設計和早期商業化試點，從而有利於臨床開發。在歐洲、中東和非洲，不同的監管和支付者環境需要跨國協調、國家層級的衛生技術評估（HTA）參與以及適應性定價策略。這有助於應對不同的准入途徑並有效率地進行多中心試驗。在亞太地區，對生物技術生態系統的快速投資、不斷擴大的臨床試驗能力以及對本地化生產的日益重視正在改變該地區的產品上市時間表。這為加速規模化生產並滿足當地監管要求創造了夥伴關係機會。

明確構成高效組織的策略能力和協作模式，並加速臨床和商業性發展進程。

免疫腫瘤領域主要企業的策略要務趨於一致，這為理解競爭行為和夥伴關係模式提供了重要線索。市場領導優先考慮平台擴充性，投資於模組化技術，以實現標靶和適應症的快速部署，同時利用共用的生產和監管途徑。這些機構還優先考慮強大的轉化醫學能力，將早期生物標記訊號轉化為適應性試驗設計和伴隨診斷策略。致力於細胞和基因療法的公司往往會在生產規模化、品質體系和商業物流方面投入大量資金，以滿足上市及上市後的需求。同時，專注於抗體或胜肽類療法的公司則透過投資新的作用機制、聯合療法和更佳的安全性來尋求差異化優勢。

為領導者提供切實可行的、優先排序的行動步驟，以整合創新、製造韌性和以支付方為中心的證據生成，從而實現永續的商業化。

產業領導者應優先考慮整合科學差異化、營運擴充性和與支付方合作的綜合方法，以將臨床潛力轉化為永續的患者獲益。首先，他們需要投資於平台策略和轉化能力，以實現快速標靶檢驗、生物標記指導的隊列選擇和適應性試驗設計，從而降低研發的不確定性。同時，他們應建立或確保冗餘的生產能力，以降低個人化藥物和細胞療法的供應風險，並發展區域夥伴關係，以降低關稅和物流風險，同時加快給藥速度。這些營運投資應與證據生成計劃保持一致，該計劃應融合隨機試驗和真實世界數據，以支持對支付方和醫療系統的價值提案。

我們透明、多方面的調查方法，包括相關人員訪談、監管審查和情境分析，為可操作的策略建議提供支援。

本報告的調查方法結合了定性和定量方法，以確保對免疫腫瘤學生態系統提供全面可靠的見解。主要研究包括對生物技術和製藥公司、臨床機構、契約製造機構和專科治療中心的高階主管進行結構化訪談和討論，以揭示營運限制、應用促進因素和策略重點。次要研究整合了同行評審文獻、監管指導文件、上市公司資訊披露、臨床試驗註冊資訊和行業會議資料，以闡明趨勢並檢驗主要研究結果。在整個研究過程中，我們運用了資料三角測量和交叉檢驗，以協調不同的觀點，並確保建議反映出趨同的證據。

以科學、營運和准入為中心的綜合規劃整合了策略要務，這些要務將決定哪些創新能夠取得臨床和商業性的成功。

總之，免疫腫瘤學正處於一個轉折點，營運上的創新和以市場為導向的證據策略對於將科學創新轉化為持續的患者獲益至關重要。細胞療法、查核點調節和疫苗技術的進步創造了新的治療機遇，但要實現這些機遇，需要在生產模式、區域定位和支付方參與方面做出謹慎選擇。關稅和供應鏈趨勢增加了策略規劃的複雜性，凸顯了採購多元化和區域夥伴關係的重要性。將轉化研究的重點與實際的營運投資和有針對性的商業化計畫結合，能夠幫助機構縮短研發週期，同時擴大病患的用藥範圍。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療方法的免疫腫瘤服務市場

  • 癌症疫苗
    • 基於細胞
    • 基因疫苗
    • 基於胜肽的
  • CAR-T療法
    • BCMA靶點
    • CD19標靶
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 單株抗體
    • 嵌合體體
    • 完全人類
    • 人性化

9. 依癌症適應症分類的免疫腫瘤學服務市場

  • 乳癌
  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
  • 肺癌
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 黑色素瘤

第10章 依最終用戶分類的免疫腫瘤服務市場

  • 醫院
    • 社區醫院
    • 大學醫院
  • 研究所
    • 學術機構
    • 政府機構
  • 專科診所
    • 日間照顧中心
    • 腫瘤診所

第11章 按通路分類的免疫腫瘤服務市場

  • 直銷
  • 經銷商網路
    • 醫療設備批發商
    • 藥品批發商
  • 線上平台
    • 公司網站
    • 第三方平台

12. 按地區分類的免疫腫瘤服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按群體分類的免疫腫瘤服務市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國免疫腫瘤服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國免疫腫瘤服務市場

第16章：中國腫瘤免疫服務市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Evotec SE
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Novartis AG
  • Pfizer Inc.
  • SGS SA
  • Syneos Health, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FDA88

The Immuno-Oncology Service Market was valued at USD 46.77 billion in 2025 and is projected to grow to USD 50.23 billion in 2026, with a CAGR of 7.70%, reaching USD 78.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 46.77 billion
Estimated Year [2026] USD 50.23 billion
Forecast Year [2032] USD 78.62 billion
CAGR (%) 7.70%

Framing the contemporary immuno-oncology landscape by integrating scientific advances, regulatory realities, and commercial imperatives into a cohesive strategic overview

The immuno-oncology field has entered a phase where scientific momentum, regulatory evolution, and commercial pressures intersect to redefine how cancer therapies are discovered, developed, and delivered. Recent advances in immune-modulating agents, cellular therapies, and precision vaccine approaches have expanded treatment possibilities across hematologic and solid tumor indications, while an increasingly sophisticated understanding of tumor biology and host immunity is reshaping clinical strategy. At the same time, health systems, payers, and patients demand clearer evidence of durable benefit, manageable toxicity, and cost-effectiveness, prompting sponsors to adopt more integrated evidence-generation pathways.

This introduction frames the report's analytical lens: we evaluate therapeutic innovation alongside practical considerations for manufacturing, distribution, and stakeholder engagement. We emphasize translational pathways from bench to bedside, mapping how pipeline differentiation, biomarker-driven patient selection, and combination strategies influence clinical development plans. The perspective balances scientific opportunity with systemic constraints, recognizing that technical feasibility must align with regulatory expectations and commercial viability. Throughout, the narrative prioritizes pragmatic insight for decision-makers seeking to position assets competitively while accelerating patient access and maintaining sustainable operations.

Charting the convergence of scientific breakthroughs, manufacturing innovation, and regulatory adaptation that is redefining immuno-oncology development and delivery

Immuno-oncology is undergoing transformative shifts driven by technological innovation, strategic collaboration, and systemic adaptation across the development lifecycle. Advancements in cell engineering and next-generation checkpoint modulation are expanding therapeutic possibilities beyond traditional single-agent approaches, enabling personalized, multi-modal regimens that aim to overcome resistance mechanisms and deepen clinical responses. Concurrently, the maturation of companion diagnostics and neoantigen identification platforms allows for more precise patient stratification, making trials more efficient and increasing the likelihood of clinically meaningful outcomes.

At the same time, manufacturing and supply chain modernization is reshaping how sponsors plan commercialization. The rise of decentralized and regionalized manufacturing models is reducing turnaround times for autologous products while allogeneic and off-the-shelf platforms are attracting investment due to their scale potential. Regulatory agencies are adapting review frameworks to accommodate complex biologics and adaptive trial designs, prompting earlier engagement between sponsors and regulators. Commercial channels are also evolving: hospitals, specialty clinics, and integrated health networks are developing centers of excellence for cell and gene therapies, which affects site selection, patient referral pathways, and reimbursement negotiations. Taken together, these shifts demand cross-functional strategies that link R&D priorities with operational capability and market access planning to realize the full potential of immuno-oncology innovations.

Assessing the operational and strategic repercussions of 2025 tariff adjustments on specialized supply chains, manufacturing placement, and clinical development planning

United States tariff policy changes in 2025 have introduced new variables into the global biopharmaceutical supply chain that disproportionately affect immuno-oncology stakeholders due to the sector's reliance on specialized raw materials, cold chain logistics, and cross-border manufacturing partnerships. Tariff adjustments on reagents, single-use consumables, and equipment can elevate direct procurement costs, forcing sponsors and contract manufacturers to reassess sourcing strategies and inventory policies. These shifts underscore the importance of diversified supplier networks and near-shoring options that reduce exposure to cross-border duties and logistical disruption while preserving quality and compliance standards.

Beyond direct cost implications, tariff dynamics influence strategic decisions around facility location, contractual terms with suppliers and distributors, and the structuring of clinical supply chains for multi-national trials. Organizations with vertically integrated manufacturing or long-term procurement agreements have greater resilience, whereas smaller entities and academic spinouts may face operational strain that could delay development timelines. In response, stakeholders are accelerating negotiations for service-level agreements, investing in tariff mitigation through alternative component specifications where feasible, and prioritizing regulatory and customs expertise in their market entry playbooks. Overall, tariff policy is prompting a recalibration of supply chain risk management and strategic planning across the immuno-oncology ecosystem.

Unpacking interdependent segmentation dynamics across therapy modalities, clinical indications, care settings, and distribution pathways to inform targeted development and commercialization strategies

Segmentation analysis highlights how therapy modality, cancer indication, end user, and distribution channel each shape strategic priorities and operational execution across the immuno-oncology value chain. Within therapy modalities, initiatives focused on cancer vaccines encompass cell-based, genetic, and peptide-based approaches, each with distinct development timelines and manufacturing requirements; cell-based vaccines demand personalized manufacturing workflows, genetic vaccines rely on nucleic acid delivery platforms and cold chain optimization, while peptide-based options offer standardized production advantages that can accelerate clinical testing. Chimeric antigen receptor T therapies include BCMA-directed and CD19-directed constructs that target different hematologic malignancies and therefore require tailored trial designs, safety monitoring, and long-term follow-up protocols. Checkpoint inhibitor programs vary by mechanism, with CTLA-4, PD-1, and PD-L1 inhibitors presenting divergent safety profiles and combination opportunities, and monoclonal antibody strategies-chimeric, fully human, and humanized-differ in immunogenicity risk, manufacturing complexity, and commercialization positioning.

Cancer indication segmentation underscores the importance of aligning modality choice with biological rationale and patient population characteristics. Breast cancer and lung cancer programs often emphasize combination regimens and biomarker enrichment to address heterogeneous tumor biology, whereas leukemia and lymphoma strategies hinge on targeted cellular therapies and hematologic-specific safety management, distinguishing protocols for acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. End user segmentation further influences deployment choices: community hospitals and university hospitals present different referral patterns and infrastructure capabilities, academic and government research institutes shape clinical trial leadership and investigator-initiated studies, and specialty clinics such as day care centers and oncology clinics offer focused treatment pathways that can streamline outpatient administration. Distribution channel segmentation informs commercialization and patient access tactics, with direct sales demanding robust field engagement, distributor networks-both medical device and pharma distributors-offering scale and logistics expertise, and online platforms, including company websites and third-party platforms, supporting digital patient engagement and product information dissemination. Together, these interlocking segment perspectives enable sponsors to prioritize investments, design differentiated clinical programs, and craft market entry strategies tailored to modality-specific requirements and end-user capabilities.

Mapping how regional infrastructure, regulatory variation, and reimbursement frameworks across global territories influence clinical adoption and commercialization choices

Regional dynamics play a decisive role in shaping research priorities, regulatory strategy, and commercialization pathways for immuno-oncology products, reflecting differences in healthcare infrastructure, reimbursement environments, and clinical trial ecosystems. In the Americas, clinical development benefits from a concentration of academic centers, established reimbursement mechanisms, and experienced contract development and manufacturing organizations, which together support complex trial designs and early commercialization pilots. Europe, Middle East & Africa presents a heterogeneous regulatory and payer landscape where cross-border coordination, country-level HTA engagement, and adaptive pricing strategies are necessary to navigate diverse access pathways and to deploy multicenter trials efficiently. In the Asia-Pacific region, rapid investment in biotech ecosystems, expanding clinical trial capacity, and a growing emphasis on local manufacturing are shifting timelines for regional launches and creating opportunities for partnerships that accelerate scale-up while addressing local regulatory requirements.

These regional differences influence prioritization across clinical indications and modalities. Regions with concentrated centers of excellence tend to adopt advanced cellular therapies earlier, while areas with strong outpatient infrastructure may favor therapies that can be administered in specialized clinics. Reimbursement and procurement policies at the regional and national levels shape value dossiers and evidence generation plans, and logistics considerations-such as cold chain connectivity and customs facilitation-affect decisions about centralized versus decentralized manufacturing. By aligning development strategies with regional capabilities and policy realities, sponsors can optimize trial site selection, regulatory engagement, and commercial rollouts to improve patient access and implementation success.

Identifying the strategic capabilities and collaborative models that distinguish high-performing organizations and accelerate clinical and commercial momentum

A concentrated set of strategic imperatives differentiates leading companies in immuno-oncology and offers insight into competitive behaviors and partnership models. Market leaders emphasize platform extensibility, investing in modular technologies that allow rapid iteration across targets and indications while leveraging shared manufacturing and regulatory pathways. These organizations also prioritize robust translational medicine capabilities that translate early biomarker signals into adaptive trial designs and companion diagnostic strategies. Companies pursuing cellular and genetic modalities tend to invest heavily in manufacturing scale-up, quality systems, and commercial logistics to ensure readiness for launch and post-launch demand, whereas organizations focused on antibody-based or peptide-based approaches invest in differentiation through novel mechanisms of action, combination strategies, and improved safety profiles.

Across the ecosystem, strategic alliances between biotechs, academic centers, and contract service providers are accelerating capability acquisition and reducing time-to-clinic. Successful firms maintain diversified distribution strategies to balance direct engagement with institutional customers and partnerships with distributor networks that can deliver logistical and regional market knowledge. Pricing and access strategies are increasingly evidence-driven, with leading companies designing post-approval evidence generation and outcomes-based agreements to address payer concerns. Finally, operational resilience-demonstrated through supply chain redundancy, regulatory foresight, and flexible manufacturing capacity-serves as a critical competitive advantage in an industry where product complexity and patient needs demand consistently high quality and on-time delivery.

Practical and prioritized action steps for leaders to align innovation, manufacturing resilience, and payer-focused evidence generation for sustainable commercialization

Industry leaders should prioritize an integrated agenda that links scientific differentiation with operational scalability and payer engagement to convert clinical promise into sustainable patient impact. First, invest in platform strategies and translational capabilities that reduce development uncertainty by enabling rapid target validation, biomarker-driven cohort selection, and adaptive trial designs. Concurrently, build or secure manufacturing capacity with redundancy to reduce supply risk for personalized and cell-based modalities, and consider regional partnerships to mitigate tariff and logistics exposure while improving time-to-infusion. These operational investments should be synchronized with evidence generation plans that blend randomized studies with real-world data to support value narratives for payers and health systems.

Commercial strategies must be tailored to end users and regional realities: develop differentiated messaging for community and university hospital systems, engage specialty clinics to expand outpatient delivery capacity, and leverage distributor networks and digital platforms to optimize access pathways. Pursue outcome-based pricing pilots where appropriate to align value with payment and to de-risk uptake for high-cost therapies. Finally, form strategic alliances with academic centers, contract developers, and diagnostic companies to share risk, accelerate enrollment, and co-develop companion diagnostics. By executing a coordinated approach that aligns R&D, manufacturing, and market access, organizations can reduce time-to-impact while maintaining financial and operational resilience.

Transparent, multi-source research methods integrating stakeholder interviews, regulatory review, and scenario analysis to underpin actionable strategic recommendations

The research methodology underpinning the report combines qualitative and quantitative approaches to ensure comprehensive and credible insight into the immuno-oncology ecosystem. Primary research involved structured interviews and consultations with senior executives across biotech, pharmaceutical, clinical institutions, contract manufacturing organizations, and specialty treatment centers to surface operational constraints, adoption drivers, and strategic priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, public company disclosures, clinical trial registries, and industry conference materials to contextualize trends and validate primary findings. Data triangulation and cross-validation were applied throughout to reconcile differing perspectives and to ensure that recommendations reflect convergent evidence.

Analytical techniques included comparative capability mapping across therapy modalities and regions, scenario analysis to assess supply chain and policy sensitivities, and thematic synthesis to identify emerging best practices in evidence generation and commercialization. Expert review panels provided iterative feedback on draft findings, enhancing practical relevance and ensuring that strategic recommendations are actionable for stakeholders across development, manufacturing, and commercial functions. The methodology emphasizes transparency and reproducibility, documenting assumptions, data sources, and interview frameworks to enable stakeholders to adapt insights to their specific contexts.

Synthesis of strategic imperatives showing how integrated scientific, operational, and access-focused planning will determine which innovations achieve clinical and commercial success

In conclusion, immuno-oncology stands at an inflection point where scientific innovation must be matched by operational ingenuity and market-oriented evidence strategies to achieve durable patient impact. Advances in cellular therapies, checkpoint modulation, and vaccine technologies create new therapeutic opportunities, but realizing those opportunities requires deliberate choices about manufacturing models, regional positioning, and payer engagement. Tariff and supply chain dynamics add complexity to strategic planning, increasing the importance of diversified sourcing and regional partnerships. By aligning translational research priorities with pragmatic operational investments and targeted commercialization plans, organizations can both shorten development cycles and support broader patient access.

Moving forward, success will accrue to those who build platform flexibility, invest in translational and regulatory expertise, and cultivate collaborative partnerships that share risk and accelerate learning. Operational resilience and evidence-based access strategies will determine which innovations move from promising science to routine clinical practice. The overarching message is that integrated planning across scientific, regulatory, operational, and commercial functions is the critical enabler for durable success in the evolving immuno-oncology landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-Oncology Service Market, by Therapy Type

  • 8.1. Cancer Vaccines
    • 8.1.1. Cell Based
    • 8.1.2. Genetic Vaccines
    • 8.1.3. Peptide Based
  • 8.2. Car-T Therapy
    • 8.2.1. Bcma Directed
    • 8.2.2. Cd19 Directed
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Chimeric
    • 8.4.2. Fully Human
    • 8.4.3. Humanized

9. Immuno-Oncology Service Market, by Cancer Indication

  • 9.1. Breast Cancer
  • 9.2. Leukemia
    • 9.2.1. Acute Lymphoblastic Leukemia
    • 9.2.2. Acute Myeloid Leukemia
    • 9.2.3. Chronic Lymphocytic Leukemia
  • 9.3. Lung Cancer
  • 9.4. Lymphoma
    • 9.4.1. Hodgkin Lymphoma
    • 9.4.2. Non Hodgkin Lymphoma
  • 9.5. Melanoma

10. Immuno-Oncology Service Market, by End User

  • 10.1. Hospitals
    • 10.1.1. Community Hospitals
    • 10.1.2. University Hospitals
  • 10.2. Research Institutes
    • 10.2.1. Academic Institutes
    • 10.2.2. Government Institutes
  • 10.3. Specialty Clinics
    • 10.3.1. Day Care Centers
    • 10.3.2. Oncology Clinics

11. Immuno-Oncology Service Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributor Networks
    • 11.2.1. Medical Device Distributors
    • 11.2.2. Pharma Distributors
  • 11.3. Online Platforms
    • 11.3.1. Company Websites
    • 11.3.2. Third Party Platforms

12. Immuno-Oncology Service Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Immuno-Oncology Service Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immuno-Oncology Service Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Immuno-Oncology Service Market

16. China Immuno-Oncology Service Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Catalent, Inc.
  • 17.6. Charles River Laboratories International, Inc.
  • 17.7. Evotec SE
  • 17.8. ICON plc
  • 17.9. IQVIA Holdings Inc.
  • 17.10. Laboratory Corporation of America Holdings
  • 17.11. Novartis AG
  • 17.12. Pfizer Inc.
  • 17.13. SGS SA
  • 17.14. Syneos Health, Inc.
  • 17.15. Takeda Pharmaceutical Company Limited
  • 17.16. Thermo Fisher Scientific Inc.
  • 17.17. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 292. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 294. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 295. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 298. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 299. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 301. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION IMMUNO-ONCOLOGY